Organogenesis (ORGO)
Develops regenerative products for advanced wound care, surgery, and sports medicine.
$1.44
vs last close−0.04 (−3.04%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 51.97% | 66.88M shares | |
|---|---|---|---|
| 137 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 111.13% | 143.00M shares | |
| 17 holders · as of Apr 24, 2026 | |||
| Strategic holders | 47.80% | 61.50M shares | |
| 3 holders · as of Dec 2, 2024 | |||
| Adds to | 210.90% | ||
128.67M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 210.90%; nothing is left for Other.
13F, as of Jun 30, 2026
137 holders · 66.88M shares · 34 new positions · 86 increased · 32 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Morgan Stanley | 11.72M | 9.11% | +104.8K | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 10.14M | 7.88% | +55.0K | Aug 11, 2026 |
| BlackRock, Inc. | 7.25M | 5.63% | +2.35M | Aug 7, 2026 |
| Dimensional Fund Advisors LP | 3.05M | 2.37% | +159.3K | Aug 11, 2026 |
| AQR Capital Management LLC | 3.01M | 2.34% | +2.13M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.91M | 2.26% | +5.1K | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 2.89M | 2.24% | +590.3K | Aug 14, 2026 |
| Assenagon Asset Management S.A. | 1.97M | 1.53% | 0 | Aug 21, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Thompson Deanincl. David Burgstahler, Avista Healthcare Partners III, L.P. +3 more | 18.00% | 28.68M | 13D | Nov 19, 2024 |
| Alan A. Adesincl. GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, GN 2016 Family Trust u/a/d August 12, 2016 +11 more | 17.60% | 22.32M | 13D | Jun 26, 2025 |
| Glenn H. Nussdorfincl. GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, GN 2016 Family Trust u/a/d August 12, 2016 | 9.70% | 12.25M | 13D | Nov 3, 2025 |
| Soleus Capital Master Fund, L.P. | 7.90% | 9.99M | 13G | Feb 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 9, 2026 | Michael Joseph Driscolldirector | Purchase | 10,000 | $2.67 | 225,707 |
| Mar 9, 2026 | Arthur S. Leibowitzdirector | Purchase | 5,000 | $2.68 | 291,014 |
| Dec 16, 2025 | Glenn H. Nussdorfdirector | Sale | 200,000 | $5.14 | 2,565,591 |
| Nov 26, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 187,957 | $5.29 | 2,765,591 |
| Nov 25, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 12,043 | $5.30 | 2,953,548 |
| Nov 24, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 100,000 | $5.34 | 2,965,591 |
| May 14, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Purchase | 251,001 | $3.09 | 251,001 |
| Jun 10, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 18,620 | $3.56 | 335,719 |
| Jun 9, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 4,156 | $3.50 | 354,339 |
| May 15, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Purchase | 107,494 | $2.99 | 358,495 |
House and Senate disclosures
Not reported.